Why is CG Oncology's operating profit declining despite revenue growth?

CG Oncology's operating profit is declining despite revenue growth due to **increasing operating expenses**. The company's total revenue for the period ending December 31, 2024, was $456 million, which represents a notable increase from the previous period. However, the operating income suffered a significant setback, reporting a loss of $31.8 million for the same period. This indicates that the company's expenses are outpacing its revenue growth, leading to a decline in profitability. |code|Ticker|Name|Date|Operating Income|Total Revenue|Operating Expenses|market_code| |---|---|---|---|---|---|---|---| |CGON|CGON.O|CG Oncology|2024 Q1|-1.6923E7|529000||185| |CGON|CGON.O|CG Oncology|2024 Q2|-1.891E7|111000||185| |CGON|CGON.O|CG Oncology|2024 Q3|-2.0403E7|43000||185| |CGON|CGON.O|CG Oncology|2024 Q4|-3.1804E7|456000||185|